Aytu Bioscience (AYTU) is up 5% for the week, and is a highly attractive investment. Just recently BlackRock has increased it’s holdings by 30%. This is bullish move and everyone should follow.
As you may have noticed AYTU Bioscience has rights for their COVID-19 serological tests and Cedars-Sinai’s Healight technology.
BlackRock Inc. increased its position in shares of Aytu Bioscience Inc (NASDAQ:AYTU) by 38.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,289 shares of the company’s stock after purchasing an additional 8,699 shares during the quarter. BlackRock Inc.’s holdings in Aytu Bioscience were worth $47,000 as of its most recent SEC filing.
AYTU opened at $1.52 on Friday. The company has a quick ratio of 1.89, a current ratio of 1.98 and a debt-to-equity ratio of 0.10. The stock has a market cap of $178.51 million, a price-to-earnings ratio of -0.85 and a beta of -0.12. Aytu Bioscience Inc has a twelve month low of $0.34 and a twelve month high of $2.99. The company’s 50-day moving average price is $1.52 and its two-hundred day moving average price is $1.15.
